- ¥123bn
- ¥159bn
- ¥30bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Nxera Pharma To Receive $8.6 Million Milestone Payment From Centessa Pharmaceuticals Following Late-Stage Development Progress
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
Table: Nxera Pharma 6-MTH group results (IFRS)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Nxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Nxera Files Patent Infringement Action In Relation To Its Minig Platform Technology
Table: Nxera Pharma -Q1 group results (IFRS)
To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient In Phase 2 Trial Of Nbi-1117570 For Adults With Schizophrenia
Achieves Second Development Milestone In Collaboration With Eli Lilly Targeting Metabolic Diseases